Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
iRegene Therapeutics is a biopharmaceutical company focused on regenerative medicine. Its stated vision is to treat major diseases that are currently difficult to cure by “reprogramming cell fate or function.” Based on the information on its website, the company is primarily building around iPSC cell therapies, with a pipeline covering indications such as Parkinson’s disease, early-onset Parkinson’s disease, multiple system atrophy, retinal degenerative diseases, and ischemic stroke.
The website presents a relatively complete R&D ecosystem: iReMeta uses AI for omics discovery; iReChem applies deep learning to support virtual screening; iReXam handles compound validation; iReDita involves gene editing and reporter cell lines; and iReCena focuses on exosome-based therapeutic delivery design. Its lead product, NouvNeu001, targets Parkinson’s disease. The site states that Phase II in China has been initiated and Phase IIa in the United States has also begun, and that the product has received FDA designations including Fast Track and RMAT. NouvNeu003, NouvNeu004, NouvSight001, and NouvNeu002 are also at various clinical or IND-preparation stages.
This is not a medical appointment or drug sales website, so no public pricing is provided. The relevant therapies are still mainly in clinical research and regulatory review. If approved in the future, actual costs will depend on manufacturing processes, indications, hospital channels, and coverage by public medical insurance and commercial insurance. Patients should not judge availability for purchase based only on information from the official website.
The strengths are a clearly focused pipeline, an advanced technical approach, and public disclosure of FDA and NMPA-related progress, as well as office/contact information in multiple locations. This makes it easier for investors, partners, and researchers to quickly understand the company’s positioning. The drawbacks are that the website provides relatively limited clinical data disclosure and lacks full papers, trial registration numbers, enrollment criteria, safety summaries, and a clear patient participation pathway. Some news items and milestones also need to be cross-checked against official regulatory databases.
It is suitable for pharmaceutical investors, regenerative medicine researchers, and BD teams at hospitals and pharmaceutical companies looking for an initial overview. It may also be useful for people following developments in Parkinson’s disease and cell therapy. Patients interested in joining clinical trials should still verify details through hospitals, clinical trial registries, or official contact channels.
The domain is the company’s official website, and the site includes a Chinese-language entry point and China contact information. Judging by the content, users in mainland China should be able to access it directly. Overall, this is more of a corporate showcase and R&D pipeline disclosure site than a consumer-facing medical service platform.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on iregene.com official site.
iregene.com is an China other provider. TG4G tracks its product information, an overall rating of 6.0/10, and a China-accessibility score of Limited (proxy recommended). Click "Visit Official Site" to reach iregene.com directly.